Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Provided By GlobeNewswire
Last update: Dec 19, 2024
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025
On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026
Read more at globenewswire.com
